Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | MARS1 | P56192 | 6/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3089952 | 1.00 | MARS1 (0.43) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27980313 | 1.00 | MARS1 (0.43) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL200899 | 1.00 | MARS1 (0.43) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27980312 | 1.00 | MARS1 (0.43) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| SCHEMBL108559 | 0.98 | MARS1 (0.44) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| SCHEMBL108560 | 0.98 | MARS1 (0.44) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| SCHEMBL3089957 | 0.98 | MARS1 (0.44) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL9081566 | 0.96 | MARS1 (0.43) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| Hydrogen Sulfide SCHEMBL9171273 | 0.96 | MARS1 (0.43) | MARS1METAP2METAP1ALDH1A1L3MBTL1 | |
| Sulfur Dioxide SCHEMBL28722439 | 0.94 | MARS1 (0.42) | MARS1METAP2METAP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409588-A | Caffeoyl amino acid methyl ester derivative and preparation method and application thereof | 西北大学 | 2025-02-11 | — | — | CN | claimed |
| CN-113912524-B | Polypeptide compound containing sulfur amide and synthesis method thereof | 华东师范大学 | 2023-12-01 | — | — | CN | claimed |
| US-20230192755-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-06-22 | — | — | US | claimed |
| EP-4137501-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-02-22 | — | — | EP | claimed |
| CN-113527399-B | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115397831-A | Compositions comprising nucleic acid oligomers | 住友化学株式会社 | 2022-11-25 | — | — | CN | claimed |
| CN-113912524-A | Polypeptide compound containing sulfamide and synthesis method thereof | 华东师范大学 | 2022-01-11 | — | — | CN | claimed |
| CN-113527399-A | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-110343520-A | Rhodamine mercury ion fluorescence probe and its application containing methionine hydrazide structure | 辽宁大学 | 2019-10-18 | — | — | CN | claimed |
| US-10144914-B2 | Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation | CORNING INCORPORATED (US) | 2018-12-04 | — | — | US | claimed |
| US-20180070612-A1 | RUMEN BY-PASS ANIMAL FEED COMPOSITION AND METHOD OF MAKING SAME | WAN FENG (US) | 2018-03-15 | — | — | US | claimed |
| CN-107708432-A | Rumen bypass animal feed composition and preparation method thereof | 拜内梅尔克公司 | 2018-02-16 | — | — | CN | claimed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | claimed |
| US-6372788-B1 | — | — | None | — | — | US | disclosed |
| CN-119638586-A | Trifluoromethyl cyclohexyl benzyl ether substituted nitrogenous organic acid derivative, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638588-A | Trifluoromethyl benzyl ether substituted amino acid derivative, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-03-18 | — | — | CN | disclosed |
| WO-1994010138-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5238922-A | Anticancer agents | MERCK & CO., INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0535731-A2 | Inhibitors of farnesyl protein transferase | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-3948971-A | N-protected-α-amino acid compounds | MERCK & CO., INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | DCK, DHPS, DHX15 | GAA 1862/4885MARS1 2408/4885METAP2 3710/4885 |
| US-20230192755-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | NSUN2, RNGTT, NSUN3 | GAA 3965/4885MARS1 204/4885METAP2 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.